Comunicados de prensa

16 sept 2020

Mylan and Development Partner, Synthon, Win Significant EPO Ruling Related to Copaxone® 40mg/mL

02 jul 2019

BC Partners to Acquire Synthon International Holding B.V.

05 oct 2017

Regulatory Approval in Europe granted for Synthon’s glatiramer acetate 40 mg/ml

13 sept 2017

European Patent Office decides in Synthon’s favor in glatiramer patent case

12 abr 2016

Synthon obtains approval for glatiramer acetate 20 mg/mL in Europe

03 ago 2015

Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis

28 abr 2015

Synthon Announces Successful Outcomes from the Open-label extension of the Phase III GATE Study of Synthon’s Glatiramer Acetate

09 oct 2014

Synthon Announces Filing of Glatiramer Acetate 40 mg/mL ANDA Containing a Paragraph IV Certification

15 abr 2014

Synthon obtains European approvals for sevelamer

27 mar 2014

Synthon announces successful outcome of the Phase III GATE study with its generic glatiramer acetate

← Previous
1 (current)
2
Next →

Press contact

Fabienne Douven, Director Corporate Communications
T +31 (0)24 372 77 00
E communications@synthon.com